Again, mice transplanted with RUNX1-ETO9a-Trp53−/−-Cas9+ cells developed AML more rapidly than those receiving RUNX1-ETO9a-Cas9+ cells with intact Trp53 (Fig. 1E). This evidence concerns the gene RUNX1 and acute myeloid leukemia.